
Sumitomo Pharma Co., Ltd.
4506.TJPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥1,418
+¥6.50 · +0.46%
4506.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteSumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Toru Kimura
- Listed since
- Jan 4, 2000
- Employees
- 3,123
Market position
Day range
Current ¥1,418
52-week range
Current ¥1,418
- Open
- ¥1,418.5
- Previous close
- ¥1,411.5
- Volume
- 2.26M
- 0.43× average
- Average volume
- 5.27M
- Average daily volume
- Market cap
- 636.11B JPY
- Beta
- 0.46
- Market reference 1
- 50-day average
- ¥1,383.56
- +2.49% above average
- 200-day average
- ¥1,951.62
- -27.34% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- 5.07×
- P/B (TTM)
- 1.51×
- P/S (TTM)
- 1.34×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 54.99%
- Operating margin
- 10.05%
- Net margin
- 23.73%
Financial health
- Debt / equity
- 0.39×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 453.29B JPY | 398.83B JPY | 314.56B JPY | 555.54B JPY | 560.04B JPY |
| Cost of goods sold | 196.4B JPY | 173.46B JPY | 157.48B JPY | 212.6B JPY | 188.86B JPY |
| Gross profit | 256.89B JPY | 225.38B JPY | 157.08B JPY | 342.95B JPY | 371.18B JPY |
| Research and development | 44B JPY | 49.87B JPY | 112.64B JPY | 131.86B JPY | 94.9B JPY |
| Selling, general, and administrative | 162.56B JPY | 160.39B JPY | 397.71B JPY | 339.21B JPY | 217.34B JPY |
| Operating expenses | 206.55B JPY | 202.96B JPY | 158.55B JPY | 331.74B JPY | 314.62B JPY |
| Interest income | 3.2B JPY | 890M JPY | 2.02B JPY | 4.51B JPY | 183M JPY |
| Interest expense | 10.19B JPY | 8.56B JPY | 4.28B JPY | 3.16B JPY | 3.05B JPY |
| Depreciation and amortization | 20.79B JPY | 25.56B JPY | 37.77B JPY | 41.26B JPY | 38.35B JPY |
| Operating income | 50.34B JPY | 22.42B JPY | −1.48B JPY | 11.2B JPY | 56.55B JPY |
| Net income | 106.87B JPY | 23.63B JPY | −314.97B JPY | −74.51B JPY | 56.41B JPY |
Company facts updated Aug 24, 2026.
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
¥28.00
2022 complete year+47.4% since 2018
¥19.00
2,018
¥16.00
2,019
¥28.00
2,020
¥28.00
2,021
¥28.00
2,022
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 30, 2023 | ¥7.00Semi-Annual | Mar 31, 2023 | Jun 28, 2023 |
Dividend | Sep 29, 2022 | ¥14.00Irregular | Sep 30, 2022 | Dec 1, 2022 |
Dividend | Mar 30, 2022 | ¥14.00Semi-Annual | Mar 31, 2022 | Jun 24, 2022 |
Dividend | Sep 29, 2021 | ¥14.00Monthly | Sep 30, 2021 | Dec 1, 2021 |
Dividend | Mar 30, 2021 | ¥14.00Semi-Annual | Mar 31, 2021 | Jun 25, 2021 |
Dividend | Sep 29, 2020 | ¥14.00Irregular | Sep 30, 2020 | Dec 1, 2020 |
Ex-dividend Mar 30, 2023
¥7.00
Semi-Annual
Record Mar 31, 2023 · Payment Jun 28, 2023
Ex-dividend Sep 29, 2022
¥14.00
Irregular
Record Sep 30, 2022 · Payment Dec 1, 2022
Ex-dividend Mar 30, 2022
¥14.00
Semi-Annual
Record Mar 31, 2022 · Payment Jun 24, 2022
Ex-dividend Sep 29, 2021
¥14.00
Monthly
Record Sep 30, 2021 · Payment Dec 1, 2021
Ex-dividend Mar 30, 2021
¥14.00
Semi-Annual
Record Mar 31, 2021 · Payment Jun 25, 2021
Ex-dividend Sep 29, 2020
¥14.00
Irregular
Record Sep 30, 2020 · Payment Dec 1, 2020
4506.T peers
Continue in GoAI
Research 4506.Tresearch.disclaimer





